PAXLOVID™ (nirmatrelvir 150mg film-coated tablets and ritonavir 100mg film-coated tablets) is now authorized in Brunei

A Special Approval of Medicinal Products During Public Health Emergency or Pandemic Situation has been granted in Brunei Darussalam for the product PAXLOVID™ (nirmatrelvir 150mg film-coated tablets and ritonavir 100mg film-coated tablets) for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19. The temporary authorization permits the supply of the product based on the approval from Emergency Use Listing (EUL) of Paxlovid granted by USFDA and is subjected to the conditions stated in the approval letter.

Package Insert

View the product Package Insert, which includes dosing, clinical data, and safety information.

Click here

Ensuring the Authenticity of PAXLOVID

Authentic PAXLOVID from Pfizer Limited will include the Pfizer name on the carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. Nirmatrelvir pink tablets have 3CL debossed on the front and PFE debossed on the back. Ritonavir white tablets have R9 debossed on the front and H debossed on the back.

The outer carton of the box has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

Pfizer is committed to patient safety and ensuring that people have accurate information about PAXLOVID, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate PAXLOVID™ treatments to protect patients from products that might be dangerous and could lead to serious and life-threatening harm.

If you suspect the PAXLOVID you have received may be counterfeit, contact Pfizer Medical Information here